Advancing colorectal cancer research through lipidomics

Area of Science:

• Oncology
• Biochemistry
• Metabolomics

Background:

• Colorectal cancer (CRC) is a major global health issue, ranking third in incidence and second in mortality worldwide.
• Projected increases in CRC incidence and mortality, especially in younger populations, highlight the urgent need for improved early detection methods.
• Current diagnostic methods like colonoscopy have limitations in adherence due to invasiveness and cost, driving research into alternative biomarkers.

Purpose of the Study:

• To explore the potential of lipidomics in identifying novel biomarkers for colorectal cancer (CRC) detection and understanding disease progression.
• To investigate specific lipid dysregulations associated with CRC, including lysophosphatidylcholine (LPC), sphingolipids, and triglycerides (TGs).

Main Methods:

• Review of recent investigations and studies focusing on lipidomics in cancer research.
• Analysis of lipid profiles in colorectal cancer patients compared to healthy controls.
• Examination of lipid class alterations across different stages of colorectal cancer progression.

Main Results:

• Decreased levels of lysophosphatidylcholine (LPC) have been observed in colorectal cancer (CRC) patients compared to healthy individuals.
• Elevated levels of specific sphingolipid species are consistently reported across multiple studies in CRC patients.
• Triglycerides (TGs) demonstrate significant differentiation across various stages of colorectal cancer (CRC) progression, indicating their potential as stage-specific markers.

Conclusions:

• Lipid dysregulations, particularly in LPC, sphingolipids, and TGs, represent promising avenues for developing innovative diagnostic tools for colorectal cancer (CRC).
• These identified lipid alterations may also serve as potential therapeutic targets for CRC.
• Further comprehensive research is essential to fully elucidate the role of these lipid changes in CRC pathogenesis and clinical application.